BRADLEY KEITH
Known title: DirectorCIK: 0001188650
Associated companies
Transaction History
| IART | ▼ Sell | Tax Withholding | 882 | $12K | 5/9/2026 | View on chart |
| IART | ▼ Sell | Tax Withholding | 392 | $5K | 5/9/2025 | View on chart |
| IART | ▲ Buy | Grant | 19,592 | $0 | 5/9/2025 | View on chart |
| IART | ▼ Sell | Tax Withholding | 202 | $5K | 5/12/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 37 | $962 | 5/12/2024 | View on chart |
| IART | ▲ Buy | Grant | 8,696 | $0 | 5/9/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 29 | $1K | 5/13/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 156 | $8K | 5/13/2023 | View on chart |
| IART | ▲ Buy | Grant | 4,486 | $0 | 5/12/2023 | View on chart |
| IART | ▲ Buy | Grant | 816 | $0 | 5/12/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 131 | $8K | 5/14/2022 | View on chart |
| IART | ▲ Buy | Grant | 3,456 | $0 | 5/13/2022 | View on chart |
| IART | ▲ Buy | Grant | 633 | $0 | 5/13/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
IART May Be 48% Undervalued Based on Cash Flow Analysis
A recent Yahoo analysis suggests Integra LifeSciences shares could be trading about 48% below their intrinsic value when cash flow is considered. The stock sits near its 13‑touch support level of $9.10 and an RSI of 41.6, indicating neither overbought nor oversold conditions. The average analyst target is $19.56, well above the current price, highlighting a potential valuation gap. This analysis may prompt a closer look at the company’s cash flow performance relative to market expectations.
IART May Be 48% Undervalued Based on Cash Flow Analysis. A recent Yahoo analysis suggests Integra LifeSciences shares could be trading about 48% below their intrinsic value when cash flow is considered. The stock sits near its 13‑touch support level of $9.10 and an RSI of 41.6, indicating neither overbought nor oversold conditions. The average analyst target is $19.56, well above the current price, highlighting a potential valuation gap. This analysis may prompt a closer look at the company’s cash flow performance relative to market expectations.